About
Lysoway Therapeutics develops brain-penetrant lysosomal ion channel modulators targeting TRPML1 and TMEM175 to restore autophagy-lysosomal function for treating neurodegenerative diseases such as Alzheimer's and Parkinson's disease.
Explore Lysoway Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.